The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ...

In November 2025, Arrowhead Pharmaceuticals announced that the U.S. FDA approved REDEMPLO (plozasiran) as the first and only siRNA treatment for adults with familial chylomicronemia syndrome, ...

Researchers of the University of the Philippines Los Baños (UPLB) have identified a gene responsible for the development of ...

The US stock market is running high, hitting record highs, bolstered in part by continued optimism around artificial ...

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

The company's annualized recurring revenue run rate jumped 30% year over year in Q3 to $2 billion. Its gross payment volume jumped 24%. Earnings almost doubled year over year to $105 million. And the ...

Five years ago this month, in November 2020, medical history was made at Richmond Pharmacology when a patient received the ...

SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA ...

Ireland punches above its weight in developing tech talent, with space-tech, fintech and medtech among the many sectors ...

Evolving patient needs are driving new drug development paradigms. For complex genetic diseases, traditional therapies often fall short. Gene therapies and nucleic acid medicines offer a way to repair ...

Arrowhead Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to ...

IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of ...